Navigation Links
Vascular Designs, Inc. Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
Date:11/14/2011

SAN JOSE, Calif., Nov. 14, 2011 /PRNewswire/ -- Vascular Designs, Inc., a medical device manufacturing company, today announced that its IsoFlow™ Infusion Catheter has received CE Mark approval for use in Europe and Canada. The IsoFlow™ Infusion Catheter enables targeted sideways perfusion, allowing physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow™ Infusion Catheter's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. The device also facilitates the LACE™ (Lateral Arterial Chemo Embolization) procedure.

(Logo: http://photos.prnewswire.com/prnh/20111114/SF06426LOGO)

"CE Mark approval is an important confirmation of the substantial benefits that patients will receive from targeted treatment of cancerous tumors," said Robert Goldman, CEO of Vascular Designs, Inc. and creator of the IsoFlow Infusion Catheter. "Directing treatment to specific locations increases the number of treatment options allowing better access to tumors and may reduce the discomfort to patients associated with the systemic application of chemotherapy."

About Vascular Designs, Inc.

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ Infusion Catheter. His personal experience of watching loved ones suffer from, and succumb to cancer, had a profound influence on the creation of IsoFlow.

With the IsoFlow Infusion Catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

The IsoFlow Infusion Catheter is in use in hospitals throughout the United States.

For more information on Vascular Designs, Inc., please visit www.vasculardesigns.com.

To view an animation illustrating the IsoFlow Infusion Catheter in action and other press materials, please visit http://www.vasculardesigns.com/news.htm.

Media Contact: Dan Orloff, Orloff Williams Partners, San Jose, 408-202-3188, dorloff@orloffwilliams.com


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  The Senior Care Pharmacy Coalition (SCPC) today ... Jason Chaffetz (R-UT) and Ranking Member ... , "Developments in the Prescription Drug Market," to ... about abusive pharmacy benefit manager (PBM) pricing practices. ... Member Elijah Cummings (D-MD) are diligent, serious lawmakers ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is ... in the field of Pharmaceuticals. Montoya is the Regulatory ... Manufacturing and ... Becton Dickinson provides healthcare institutions, clinical laboratories ... throughout fifty countries across the globe. ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS ... Designed to provide the most effective tattoo removal today, Dr. Bentkover is the only ... Developed by Cynosure, the PicoSure has been approved by the Food and Drug Administration ...
(Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, ... an illness. Migraines are a severe form of a headache and often are accompanied ... the pain on their worst enemy, the feeling can last for many hours and ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) announced ... in New York City on Thursday, January 21, 2016. Kingsley R. Chin, ... alumnus of the varsity Columbia soccer program) spoke at the event, offering professional ...
Breaking Medicine News(10 mins):